LAMATTINA JOHN L
SEC Form 4 insider trading activity
LAMATTINA JOHN L has filed 4 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Jun 12, 2026.
On the most recent filing, LAMATTINA JOHN L is listed as Director at LIGAND PHARMACEUTICALS INC. Inside the rolling window, LAMATTINA JOHN L reported no open-market purchases and 3 open-market sales totaling $2.4M in LGND. The largest disclosed transaction in the window is a sale of 4,591 LGND shares on Jun 10, 2026, worth $1.2M.
Companies traded
Other insiders at LGND
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.4M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has LAMATTINA JOHN L made?
LAMATTINA JOHN L has filed 4 SEC Form 4 filings (11 transaction rows) across 1 company since 2025.
Which companies does LAMATTINA JOHN L trade?
LAMATTINA JOHN L has filed SEC Form 4 disclosures for 1 company, including LGND.
When was LAMATTINA JOHN L's most recent SEC Form 4 filing?
LAMATTINA JOHN L's most recent SEC Form 4 filing on Tracefour is dated Jun 12, 2026.
What is LAMATTINA JOHN L's total buy and sell value in the current window?
Inside the rolling retention window, LAMATTINA JOHN L bought $0 and sold $2.4M based on SEC Form 4 filings.
What was LAMATTINA JOHN L's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,591 LGND shares on 2026-06-10, worth $1.2M, per SEC Form 4 filings.